News
Company News: Curetis Sharpens Focus on Near-Term Strategic Value Drivers
— Business focus on U.S. commercialization, strategic partnering, Ares Genetics and asset monetization
— Reduction of net cash consumption by up to 50% (YoY) expected
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced an update on its strategic value creation priorities for 2019 and beyond. Read more…
Company News: Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generation COP Allergy Vaccine
— The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability
— Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible
Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study of the second-generation COP allergy vaccines based on its research collaboration with Mymetics SA, a leader in the research and development of virosome-based vaccines. Read more…
Company News: Cardior Receives EUR 1.01 Million Grant to Identify Novel Oligonucleotides for the Treatment of Chronic Heart Failure
— Collaboration with Hannover Medical School (MHH)
Cardior Pharmaceuticals GmbH, a company focused on the development of noncoding RNA (ncRNA) therapeutics for patients with myocardial infarction and heart failure, today announced it has been granted EUR 1.01 million funding for a joint research project with the Institute of Molecular and Translational Therapeutic Strategies (IMTTS) at Hannover Medical School (MHH). Read more…
Company News: BellaSeno Receives RegMedNet Award for Cultivating Excellence
– Leipzig-based start-up prepares for first clinical trial in 2019
BellaSeno GmbH, a company developing absorbable implants using additive manufacturing technology , today announced it was awarded the 2018 Award for Cultivating Excellence by RegMedNet for its innovation, creativity, professionalism and investment in young professionals. BellaSeno won the public vote after five finalists were shortlisted by an expert jury. The award was established in 2017 to increase the visibility of the most valuable players in regenerative medicine.